News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Adamis Pharmaceuticals Prostate Cancer Drug APC-200 Granted Patents in Singapore and South Africa



9/22/2011 10:26:05 AM

SAN DIEGO--(BUSINESS WIRE)--Adamis Pharmaceuticals Corporation (OTCBB: ADMP), today announced the technology which constitutes its compound APC-200 was recently granted patents in Singapore and South Africa. These patents significantly strengthen the Adamis APC-200 patent portfolio for the use of APC-200 in the treatment of early and late stage prostate cancer.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES